Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 3

Status

Completed 3Terminated 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4Breast 4Thoracic 3Sarcoma 2Genitourinary 2Dermatologic 2Gynecologic 1

Conditions

Rectal Neoplasms 1Pancreatic Neoplasms 1Gastrointestinal Stromal Tumors 1Esophagogastric Cancer 1Colonic Neoplasms 1

Interventions

Oxaliplatin 780Fluorouracil 638Capecitabine 575Gemcitabine 478Leucovorin 459Bevacizumab 445Irinotecan 444Cisplatin 338Radiotherapy 283Cetuximab 252Paclitaxel 180S 1 (combination) 176pembrolizumab 173Docetaxel 156Drug Therapy 147Nivolumab 146sintilimab 143tislelizumab 131apatinib 131130-nm albumin-bound paclitaxel 128Folfox protocol 121durvalumab 119Albumin-Bound Paclitaxel 117camrelizumab 107lenvatinib 106Panitumumab 106regorafenib 102Surgical Procedures, Operative 102Sorafenib 99Radiation 88

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × STA 9090 × Gastrointestinal × Clear all
NCT01167114 2023-11-02

STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer

Massachusetts General Hospital

Phase 2 Completed
28 enrolled
Gastrointestinal

Esophagogastric Cancer

NCT01039519 2016-03-10

A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)

Synta Pharmaceuticals Corp.

Phase 2 Completed
27 enrolled 22 charts
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT01111838 2015-11-20

Clinical and Translational Study of STA-9090

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
20 enrolled 6 charts
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT01227018 2014-07-23

PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer

Vanderbilt-Ingram Cancer Center

Phase 2 Terminated
15 enrolled 9 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡